BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2017;13:483-490. [PMID: 28165830 DOI: 10.1080/17425255.2017.1292253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gaur N, Malhotra V, Agrawal D, Singh SK, Beniwal P, Sharma S, Jhorawat R, Rathore V, Joshi H. Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. J Clin Exp Hepatol 2020;10:189-93. [PMID: 32405174 DOI: 10.1016/j.jceh.2019.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:901-10. [PMID: 30058394 DOI: 10.1080/17425255.2018.1506765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 El-wekil M, Ali HRH, Marzouk AA, Ali R. Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids. RSC Adv 2018;8:13292-300. [DOI: 10.1039/c7ra13719b] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
4 Néant N, Solas C. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. Int J Antimicrob Agents 2020;56:105571. [PMID: 30394302 DOI: 10.1016/j.ijantimicag.2018.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Derayea SM, Abdel-Lateef MA, Omar MA, Ali R. Thin-layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma. Luminescence 2020;35:1048-55. [PMID: 32350964 DOI: 10.1002/bio.3816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guan XD, Tang XG, Zhang YJ, Xie HM, Luo L, Wu D, Chen R, Hu P. Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. Front Pharmacol 2020;11:617122. [PMID: 33584296 DOI: 10.3389/fphar.2020.617122] [Reference Citation Analysis]
7 Rubino C, Trapani S, Indolfi G. Sofosbuvir/velpatasvir for the treatment of Hepatitis C in pediatric patients. Expert Rev Gastroenterol Hepatol 2021. [PMID: 34338120 DOI: 10.1080/17474124.2021.1963231] [Reference Citation Analysis]
8 Lalanne S, Jézéquel C, Tron C, Verdier MC, Mercerolle M, Pronier C, Guyader D, Lemaitre F. Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. Ther Drug Monit 2020;42:163-4. [PMID: 32195986 DOI: 10.1097/FTD.0000000000000718] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Omar MA, Abdel-Lateef MA, Ali R, Derayea SM. Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma. Luminescence 2018;33:1249-56. [PMID: 30144265 DOI: 10.1002/bio.3542] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
10 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]